Pear Therapeutics

Press Releases

Pear Therapeutics to Participate in Goldman Sachs Digital Health: Biosensors, AI, and the Future of Data Analytics Conference and 26th Annual BioCentury Future Leaders in the Biotech Industry Conference

Boston, April 4, 2019 – Pear Therapeutics, Inc., the leader in prescription digital therapeutics (PDTs), today announced its participation in the Goldman Sachs Digital Health: Biosensors, AI, and the Future of Data Analytics Conference and the 26thAnnual BioCentury Future Leaders in the Biotech Industry Conference. Details below:

  • Corey McCann, M.D., Ph.D., President and CEO, will participate in a digital therapeutics panel at the Goldman Sachs Digital Health: Biosensors, AI, and the Future of Data Analytics Conference on April 11 at 9:20 a.m. at the Goldman Sachs Conference Center in New York
  • Chris Guiffre, J.D., M.B.A., Chief Financial Officer and Chief Operating Officer, will present at the 26thAnnual BioCentury Future Leaders in the Biotech Industry Conference on April 12 at 9:30 a.m. at the Millennium Broadway Hotel and Conference Center in New York

Pear Therapeutics is a privately held, prescription digital therapeutics company developing clinically validated, FDA-authorized software applications to treat serious disease.

 

About Pear Therapeutics
Pear Therapeutics is the leader in prescription digital therapeutics. We aim to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has a pipeline of products and product candidates across therapeutic areas, including severe psychiatric and neurological conditions. Our lead product, reSET®, treats Substance Use Disorder and was the first prescription digital therapeutic to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O™, for the treatment of Opioid Use Disorder, received marketing authorization from the FDA in December 2018. For more information, visit us at www.peartherapeutics.com.

 

Media and Investors:
Amanda Galgay
amanda.galgay@peartherapeutics.com

Back